Government Launches Consultation on Future of UK Human Fertilisation and Tissue Regulators
By Ayesha Ahmad,
BioNews
| 07. 02. 2012
The UK Government has launched a consultation on the future of the Human Fertilisation and Embryology Authority (HFEA) and Human Tissue Authority (HTA) amid proposals to transfer the regulators' functions elsewhere.
The UK-wide consultation asks for views on whether the HFEA and HTA should be abolished and the regulator's responsibilities reallocated to the Care Quality Commission (CQC), with the HFEA's research functions transferred to the newly formed Health Research Authority – or if some functions should be transferred to organisations other than the CQC. It also asks for views on whether the HFEA and HTA should continue to retain their functions, with further cost-savings made.
Read more...
Related Articles
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
Alice Wong, founder of the Disability Visibility Project, MacArthur Genius, liberationist, storyteller, writer, and friend of CGS, died on November 14. Alice shone a bright light on pervasive ableism in our society. She articulated how people with disabilities are limited not by an inability to do things but by systemic segregation and discrimination, the de-prioritization of accessibility, and the devaluation of their lives.
We at CGS learned so much from Alice about disability justice, which goes beyond rights...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...
